

REMARKS UNDER 37 CFR § 1.116

Formal Matters

Claims 104-108, 121, 123, 127-135, and 142 are now pending in this application, following the present amendments.

Claim 104 has been amended to more particularly point out and distinctly claim the invention. The amendment to the claim was made solely in the interest of expediting prosecution, and is not to be construed as an acquiescence to any objection or rejection of any claim.

Support for the amendments may be found in the specification on page 32, line 22 to page 33, line 10, as originally filed. As such, no new matter is added by the amendments.

Please replace claim 104 with the clean version provided above.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached is captioned "**VERSION WITH MARKINGS TO SHOW CHANGES MADE.**"

Applicants respectfully request reconsideration of the application in view of the remarks made herein.

Interview summary

Applicants wish to extend their gratitude to Examiner Huynh for the courtesy of allowing an interview with Applicants' representative, James S. Keddie, on November 6, 2002.

Potential claim amendments, the Statement of Availability, the ATCC catalog entry for 293 cells, and arguments for response were discussed.

Examiner Huynh suggested that amending claim 104 from "binds to all of human, mouse and rat connective tissue growth factors" to "binds to human, mouse and rat connective tissue growth factors" may remove some issues.

The Response in General

Claims have been rejected for lack of enablement and lack of written description.

Applicants have provided an enabling disclosure for what they are claiming and have adequately described what they are claiming. Specifically, applicants have provided detailed methods of how to make the claimed antibodies, and have provided working examples of at least 9 claimed antibodies. All one of skill in the art would have to do to make hundreds or more of the claimed antibodies is perform the described methods. Since the production of hundreds more of the claimed antibodies is well within the ability of one of skill in the art using the methods in the specification, and because a representative number of examples of this genus are described in the specification, the rejections should be withdrawn.

To the extent a further discussion is believed necessary, the Examiner is respectfully referred to the following.

Rejections under 35 U.S.C. § 112, First Paragraph

Enablement:

Claims 104-108, 121, 123, 127-135 and 142 were rejected under 35 U.S.C. § 112, first paragraph, for containing subject matter which was not described in such a way as to enable one of skill in the art to make and use the invention. Specifically, the Office Action asserts that the specification does not provide any guidance as how to make and use the subject antibodies and, as such, the specification as filed fails to enable one skill in the art to practice the invention without undue experimentation. The Office Action further asserts that because the antibodies are not enabled by the specification, the subject labeled antibody, kits and insoluble carriers are also not enabled by the specification.

The law is clear that “[t]he test of enablement is whether one reasonably skilled in the art could make or use the invention from the disclosures in the patent coupled with information known in the art without undue experimentation.”¹ The Office is reminded that extensive experimentation may be performed, so long as the experimentation is routine, and that every species within a genus does not have

¹ *United States v. Telectronics, Inc.*, 8 USPQ 2d 1217, 1233 (Fed. Cir. 1988), cert. denied, 490 U.S. 1046 (1989). See also, *Genentech, Inc. v. Novo Nordisk*, 42 USPQ 2d 1001 (Fed. Cir. 1997), cert. denied, 522 U.S. 963 (1997); *Scripps Clinic and Research Foundation v. Genentech, Inc.*, 18 USPQ 2d 1001 (Fed. Cir. 1991).

to be operative for a claim to be fully enabled.

The Applicants respectfully submit that the specification and the amended claims, coupled with the information known in the art, would enable one of skill in the art to use the invention without undue experimentation.

Statement of Availability

The Office indicates that deposit of hybridomas FERM BP-6208 and FERM BP-6209, and the 293-T cell line are required to satisfy the enablement requirement of claims 105-108, 127 and 155.

A "Statement of Availability" is attached hereto acknowledging the deposit criteria noted by the Examiner. Also, applicants have attached a copy of a catalog that shows details of the cell line available from ATCC. This copy serves as clear and convincing evidence that the 293-T cell line is "readily available to the public" as required by 37 CFR 1.802(b). The catalog details are available from the ATCC web site below.

<http://phage.atcc.org/cgi-bin/searchengine/longview.cgi?view=ce,691450,CRL-1573&text=CRL-1573>

Since the deposit has been made under the terms of the Budapest Treaty, claims directed to these deposits, e.g. claims 108 and 127 should be considered enabled.

The specification provides sufficient of guidance

The Office Action asserts that the specification does not provide any guidance as to how to make and use antibodies that bind to the mouse, human and rat CTGF.

Applicants have provided at least 9 working examples of IgG isotype non-human monoclonal antibodies that bind to human, mouse and rat CTGFs. Namely, as in Fig.1 of the present application, at least 8-64-6 (FERM BP-6209), 8-86-2 (FERM BP-6208), 8-97-3, 8-149-3, 15-38-1, 17-132, 24-53, 24-67 and 2-228-1 are examples of monoclonal antibodies that have this characteristic. A total of 5 monoclonal antibodies of this group of 9 CTGF binding non-human monoclonal antibodies inhibit the binding of human CTGF to human kidney-derived fibroblast cell line 293-T (i.e., 8-64-6, 8.86-2, 8-149-3, 17-132 and 2-228-1). As such, one of skill in the art, in order to produce, for example, hundreds of monoclonal antibodies that bind to human, mouse and rat CTGF would merely have to repeat the protocol, as described in detail in Example 4 (<4-1> through <4-13-3>), on pages 74-89 of the specification. As such, since the specification provides several working examples of subject monoclonal antibodies and has

provided detailed guidance on how to produce more of such monoclonal antibodies, such antibodies would be made and used without any undue experimentation.

In this respect it is notable that a sufficient number of the non-human monoclonal antibodies produced by the methods described in Example 4 (<4-1> through <4-13-3>) bind to human, mouse and rat CTGF, and further that most of these antibodies have an inhibitory effect on the binding of CTGF and 293-T cells.

Antibody production is a mature art

Furthermore, Applicants assert that antibody production, in general, is a mature art in which the levels of unpredictability are low.

Since their groundbreaking work on monoclonal antibody production by Köhler & Milstein in 1975, this art has advanced to such a point that antibodies are produced by one of skill in the art using very routine methodologies (for example, see Harlow et al., *Antibodies: A Laboratory Manual*, First Edition (1988) Cold Spring Harbor, N.Y.). In fact, the "Synopsis of Application of Written Description Guidelines" (hereafter "Synopsis"; posted on the USPTO world wide website on March 1, 2000) supports this assertion. With respect to antibodies, the Synopsis states, on page 60, that "This is a mature technology where the level is high and advanced".

As such, since antibody production is a mature art, one of skill in the art needs little guidance in practicing these methods.

The specification provides an enabling disclosure for "a portion of" a monoclonal antibody

The Office Action has stated that there is insufficient guidance as to which portion of a non-human monoclonal can inhibit the binding of human CTGF to 293 cells.

Portions of an antibody are very well understood by one of skill in the art to mean antibodies that are fragments of a full length antibody that still retain binding activity. In these cases the constant domain is usually at least partially deleted, thus leaving an antibody fragment that can still bind antigen. Making such antibodies (e.g. deleting certain amino acids from a full length antibody) is very well understood in the art, and is described in the specification on page 32, line 22 to page 33, line 10. Further working examples of fragments of subject monoclonal antibodies are provided in Example 8, on page 103 line 29

to 104 line 24.

Solely for the interest of expediting prosecution, applicant amended pending claim 104 so as to more particularly point out "a portion" invention under the above support in the present application as originally filed.

As such, in contrast to the assertions of the Office Action, the specification provides significant guidance as to a "portion" of a monoclonal antibody and would make such an antibody with no undue experimentation.

Summary of response to enablement rejection

Figures 1 of the specification show many of the non-human monoclonal antibodies that binds to CTGF of one mammalian species (e.g. human) will bind to a CTGF of other mammalian species (e.g. mouse or rat) and that most of these cross-reactive antibodies inhibit binding of CTGF and 293-T cells. This knowledge, coupled with the detailed methods for producing a CTGF-binding monoclonal antibody provided in the specification, would undeniably allow one of skill in the art make and use the claimed antibodies without undue experimentation. Applicants further assert that since the subject antibodies are fully enabled by the specification, the subject labeled antibody, kits and insoluble carriers are also fully enabled.

Applicants assert that the invention can be practiced by one of skill in the art without undue experimentation, and, as such, the rejection of these claims under 35 U.S.C. § 112, first paragraph (enablement) may be withdrawn.

Written Description:

Claims 104-108, 121, 123, 127-135 and 142 were further rejected under 35 U.S.C. § 112, first paragraph, for containing subject matter which was not described in such a way as to convey possession of the claimed invention. Specifically, the Office Action asserts that the specification only discloses two monoclonal antibodies that cross-react with human, mouse and rat CTGF and further asserts that the specification fails to provide a representative number of species to describe genus.

Applicants respectfully traverse this rejection.

"Connective tissue growth factor" in the subject claims

In advance of detailed traversal below, applicants make clear the "Connective tissue growth factor (CTGF)" recited in the claims. The examiner states as below on page 7, lines 30 to page 8, line 1 of the outstanding office action.

" However, the amended claims still read on any non-human monoclonal antibody or portion thereof which (a) that binds to and (b) has IgG isotype where connective tissue growth factor is any CTGFs such as TGFbeta, PDGF, FGF, and EGF." (emphasis added)

The "CTGF" to which the subject monoclonal antibodies bind is the CTGF as defined on page 18, line 6 to page 19, line 25 of the present application and not TGFbeta, PDGF or EGF. CTGF is different molecule from any of the TGFbeta, PDGF or EGF.

The Written Description Guidelines indicate that such the subject claims are adequately described

The "Synopsis of Application of Written Description Guidelines" (hereafter "Synopsis"; posted on the USPTO world wide website on March 1, 2000), to which Examiners of the USPTO must adhere, describes an example (Example 16) similar to that of the Applicants.

The specification of this example discloses a purified 55kDa polypeptide and contemplates but does not teach an antibody that specifically binds to this polypeptide. In this example the claim "An isolated antibody capable of binding to antigen X" is made and even without a working example. The guidelines state that "The disclosure meets the requirement under 35 USC 112 first paragraph as providing an adequate written description of the claimed invention."

In the instant case, the applicants have provided a purified antigen (e.g. rat, human or mouse CTGF) and further have provided several working examples of monoclonal antibodies that bind to the antigen. When viewed using the reasoning presented by these Guidelines, the subject matter of the instant claims is adequately described in the specification.

The specification provides a sufficient number of species to describe the genus

The Office also asserts that the specification fails to describe additional representative species of non-human monoclonal antibodies that bind to CTGF, and that one of skill in the art would reasonably conclude that the specification fails to provide a representative number of species to describe the genus.

As noted above, applicants have provided at least 9 working examples of IgG isotype non-human monoclonal antibodies which bind to human, mouse and rat CTGFs. Namely, as in Fig.1 of the present application, at least 8-64-6 (FERM BP-6209), 8-86-2 (FERM BP-6208), 8-97-3, 8-149-3, 15-38-1, 17-132, 24-53, 24-67 and 2-228-1 have this characteristic. A total of 5 of this group of the 9 non-human monoclonal antibodies inhibit the binding of human CTGF to human kidney-derived fibroblast cell line 293-T (i.e., 8-64-6, 8.86-2, 8-149-3, 17-132 and 2-228-1). As such, a relatively sufficient number of claimed monoclonal antibodies are disclosed in the specification.

Because a relatively sufficient number of claimed monoclonal antibodies are disclosed, Applicants assert that a representative number of species of the claimed genus is described and, as such, one of skill in the art would recognize that the genus is adequately described.

The specification adequately describes "portions." of antibodies

The Office Action has stated that there is insufficient description of portions of a non-human monoclonal antibody can inhibit the binding of human CTGF to 293-T cells.

As respectfully mentioned above, portions of an antibody are very well understood by one of skill in the art to mean antibodies that are fragments of a full length antibody that still retain binding activity. In these cases the constant domain is usually at least partially deleted, thus leaving an antibody fragment that can still bind antigen. Making and using such antibodies (e.g. deleting certain amino acids from a full length antibody) is very well understood in the art, and such antibodies are described in the specification on page 32, line 22 to page 33, line 10. Further working examples of fragments of subject monoclonal antibodies are provided in Example 8, on page 103 line 29 to 104 line 24.

Solely for the interest of expediting prosecution, applicant amended pending claim 104 has been amended to more particularly point out "a portion" invention under the above support in the present application as originally filed.

As such, in contrast to the assertions of the Office Action, the specification provides significant description of portions of monoclonal antibodies.

Summary of response to written description rejection

In summary, Applicants assert that one of skill in the art would recognize that at least 9 working examples of non-human monoclonal antibodies that bind human, mouse and rat CTGFs, and at least 5 working examples of the 9 non-human monoclonal antibodies that inhibit the binding of human CTGF 293-T cells are adequate representations of the claimed genera, especially in light of the USPTO Guidelines which indicate that not even one example is actually needed. Applicants further assert that since the subject antibodies are adequately described, the subject labeled antibody, kits and insoluble carriers are also adequately described.

As such, the specification provides adequate description of the subject matter encompassed by the claims and the rejection may be withdrawn.

Conclusion


Applicant submits that all of the claims are in condition for allowance, which action is requested. If the Examiner finds that a telephone conference would expedite the prosecution of this application, please telephone the undersigned at the number provided.

The Commissioner is hereby authorized to charge any underpayment of fees associated with this communication, including any necessary fees for extensions of time, or credit any overpayment to Deposit Account No. 50-0815, order number SHIM006.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: 11-08-2002

By:


James S. Keddie Ph.D.
Registration No. 48,920

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS

Claim 104 is amended, as shown below.

104. (Thrice Amended) A non-human monoclonal antibody or a portion thereof selected from the group consisting of F(ab')₂, Fab, Fab', Fv, sFv, dsFv and dAb, which (a) binds to all of human, mouse and rat connective tissue growth factors (CTGFs) and (b) has the IgG isotype.



; 0 199741

2 / 3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Tamatani et al.
Title: Monoclonal Antibody Against Connective Tissue Growth Factor and Medicinal Uses Thereof
Appl. No.: 09/582,337
Filing Date: September 18, 2000
Examiner: P. Huynh
Art Unit: 1644
Atty. Docket No.: SHIM-006

STATEMENT OF AVAILABILITY

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

Sir:

I, Teruo Daito, Director of Intellectual property, of Japan Tobacco, Inc., declare:

1. A deposit of hybridoma clones 8-86-2 and 8-64-6 has been made and accepted under the provisions of the Budapest Treaty at the National Institute of Bioscience and Human Technology at the Agency of Industrial Science and Technology, the Ministry of International Trade and Industry of 1-1-3, Higashi, Tsukuba, Ibaraki, 305, Japan for patent purposes and assigned the following reference numbers FERM BP-6208 and FERM BP-6209, respectively;
2. All restrictions on the availability to the public of the culture deposited will be irrevocably removed upon the granting of a patent from the above-identified application;
3. The deposit will be maintained for a period of 30 years after the date of deposit or 5 years after the last request for a sample or for the enforceable life of the patent, whichever is longer.

4. The deposit will be replaced if viable samples cannot be dispensed by the depository; and
5. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued therefrom;

Further declarant sayeth not.

Signed this 30 day of October 2002

Signature:



Printed Name:

Teruo Daito



View Cart

SEARCH CATALOGS | SITE MAP | CONTACT US

ORDER | PRODUCTS | PROGRAMS & SERVICES | HOME

You may continue your word search on Cell Lines by typing in your search criteria below or go back to the [Cell Lines menu](#) and begin a new search. To choose another collection, go back to the main menu by clicking on "search catalogs" above. For complex searches, using boolean operators, the following characters must be used: & (for AND), | (for OR), ^ (for AND NOT). An asterisk (*) is used as the wildcard. For more information please review the [Search Help](#).

CRL-1573

Word Search

Clear Search

For query options, please read the [search help](#).

Cell Lines	
ATCC Number:	CRL-1573 order this item
Organism:	<i>Homo sapiens</i> (human)
Designation:	293
Depositors:	F.L. Graham
Tissue:	kidney, transformed with adenovirus 5 DNA
Tumorigenic:	yes. Tumors developed within 21 days at 100% frequency (5/5) in nude mice inoculated subcutaneously with 10 ⁷ cells. [RF32725]
Receptors Expressed:	vitronectin
Morphology:	epithelial
Comments:	The 293 cell line is a permanent line of primary human embryonal kidney transformed by sheared human adenovirus type 5 (Ad 5) DNA. [RF32725] The cells express the transforming gene of adenovirus 5. Although an earlier report suggested that the cells contained Adenovirus 5 DNA from both the right and left ends of the viral genome [RF32764], it is now clear that only left end sequences are present. [RF50113] The line is excellent for titrating human adenoviruses. The cell line does not adhere to the substrate when left at room temperature for any length of time, therefore, live cultures may be received with the cells detached. The cells will re-attach to the flask over a period of several days in culture at 37C. The cells express an unusual cell surface receptor for vitronectin composed of the integrin beta-1 subunit and the vitronectin receptor alpha-v subunit. [RF33793] Purified DNA from this line is available as ATCC 45504 (25 micrograms) and ATCC 45505 (100 micrograms). The Ad5 insert was cloned and sequenced, and it was determined that a colinear segment from nts 1 to 4344 is integrated into chromosome 19 (19q13.2). [RF50113]
Age Stage:	fetus
Growth Properties:	adherent
Virus Susceptibility:	very sensitive to human adenoviruses [RF32725]
Karyotype:	This is a hypotriploid human cell line. The modal chromosome number was 64, occurring in 30% of cells. The rate of cells with higher ploidies was 4.2 %. The der(1)t(1;15) (q42;q13), der(19)(3;19) (q12;q13), der(12)t(8;12) (q22;p13), and four other marker chromosomes were common to most cells. Five other markers occurred in some cells only. The marker der(1) and M8 (or Xq ⁺) were often paired. There were four copies of N17 and N22. Noticeably in addition to three copies of X chromosomes, there were paired Xq ⁺ , and a single Xp ⁺ in most cells.
Subculturing:	Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach. Add fresh culture medium, aspirate and dispense into new culture flasks.
Split Ratio:	A subcultivation ratio of 1:2 to 1:4 is recommended
Fluid Renewal:	Every 2 to 3 days
Freeze Medium:	culture medium 95%; DMSO, 5%
DNA Profile (STR):	Amelogenin: X CSF1PO: 11,12 D13S317: 12,14 D16S539: 9,13 D5S818: 8,9 D7S820: 11,12 TH01: 7,9,3 TPOX: 11 WVA: 16,19
References:	RF32031: Xie QW et al. Complementation analysis of mutants of nitric oxide synthase reveals that the

active site requires two hemes. Proc. Natl. Acad. Sci. USA 93: 4891–4896, 1996 PubMed: 96209828
 RF32042: De Costa LT et al. Converting cancer genes into killer genes. Proc. Natl. Acad. Sci. USA 93: 4192–4196, 1996 PubMed: 96210616
 RF32725: Graham FL et al. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36: 59–72, 1977 PubMed: 77229557
 RF32764: Graham FL et al. Defective transforming capacity of adenovirus type 5 host-range mutants. Virology 86: 10–21, 1978 PubMed: 78205587
 RF33120: Harrison T et al. Host-range mutants of adenovirus type 5 defective for growth in HeLa cells. Virology 77: 319–329, 1977 PubMed: 77129592
 RF33793: Bodary SC and McLean JW. The integrin beta 1 subunit associates with the vitronectin receptor alpha v subunit to form a novel vitronectin receptor in a human embryonic kidney cell line. J. Biol. Chem. 265: 5938–5941, 1990 PubMed: 90202850
 RF37982: Goodrum FD and Ornelles DA. The early region 1B 55-kilodalton oncoprotein of adenovirus relieves growth restrictions imposed on viral replication by the cell cycle. J. Virol. 71: 548–561, 1997 PubMed: 97138357
 RF38421: Loeffler S et al. CD9, a tetraspan transmembrane protein, renders cells susceptible to canine distemper virus. J. Virol. 71: 42–49, 1997 PubMed: 97138295
 RF42151: Hu SX et al. Development of an adenovirus vector with tetracycline-regulatable human tumor necrosis factor alpha gene expression. Cancer Res. 57: 3339–3343, 1997 PubMed: 97413605
 RF42260: Kolanus W et al. alphaBeta2 integrin/LFA-1 binding to ICAM-1 induced by cytohesin-1 a cytoplasmic regulatory molecule. Cell 86: 233–242, 1996 PubMed: 96319726
 RF42346: Stauderman KA et al. Characterization of human recombinant neuronal nicotinic acetylcholine receptor subunit combinations alpha 2 beta 4, alpha 3 beta 4 and alpha 4 beta 4 stably expressed in HEK293 cells. J. Pharmacol. Exp. Ther. 284: 777–789, 1998 PubMed: 98122961
 RF42369: Bartz SR et al. Human immunodeficiency virus type 1 cell cycle control: Vpr is cytostatic and mediates G2 accumulation by a mechanism which differs from DNA damage checkpoint control. J. Virol. 70: 2324–2331, 1996 PubMed: 96183878
 RF42575: Sandri-Goldin RM and Hibbard MK. The herpes simplex virus type 1 regulatory protein ICP27 coimmunoprecipitates with anti-sm antiserum, and the C terminus appears to be required for this interaction. J. Virol. 70: 108–118, 1996 PubMed: 96099420
 RF42673: Ansieau S et al. Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation. Proc. Natl. Acad. Sci. USA 93: 14053–14058, 1996 PubMed: 97098519
 RF42735: Zhang J et al. Dynamin and beta-arrestin reveal distinct mechanisms for G protein-coupled receptor internalization. J. Biol. Chem. 271: 18302–18305, 1996 PubMed: 96324889
 RF42754: Oppermann M et al. Monoclonal antibodies reveal receptor specificity among G-protein-coupled receptor kinases. Proc. Natl. Acad. Sci. USA 93: 7649–7654, 1996 PubMed: 96353872
 RF42760: Xia Y et al. Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury. Proc. Natl. Acad. Sci. USA 93: 6770–6774, 1996 PubMed: 96270618
 RF42764: Zhu X et al. Cell cycle-dependent modulation of telomerase activity in tumor cells. Proc. Natl. Acad. Sci. USA 93: 6091–6095, 1996 PubMed: 96234095
 RF42806: Uebel VN et al. Functional differences in Kv1.5 currents expressed in mammalian cell lines are due to the presence of endogenous Kvbeta2.1 subunits. J. Biol. Chem. 271: 2406–2412, 1996 PubMed: 96161969
 RF42836: Abell A et al. Deletions of portions of the extracellular loops of the lutropin/choriogonadotropin receptor decrease the binding affinity for ovine luteinizing hormone, but not human choriogonadotropin, by preventing the formation of mature cell surface receptor. J. Biol. Chem. 271: 4518–4527, 1996 PubMed: 96224039
 RF42842: Tiberi M et al. Differential regulation of dopamine D1A receptor responsiveness by various G protein-coupled receptor kinases. J. Biol. Chem. 271: 3771–3778, 1996 PubMed: 96216484
 RF42853: Shahrestanifar M et al. Studies on inhibition of mu and delta opioid receptor binding by dithiothreitol and N-ethylmaleimide. His223 is critical for mu opioid receptor binding and inactivation by N-ethylmaleimide. J. Biol. Chem. 271: 5505–5512, 1996 PubMed: 96215005
 RF42865: Boring L et al. Molecular cloning and functional expression of murine JE (monocyte chemoattractant protein 1) and murine macrophage inflammatory protein 1alpha receptors. J. Biol. Chem. 271: 7551–7558, 1996 PubMed: 96205938
 RF42866: Noonberg SB et al. Evidence of post-transcriptional regulation of U6 small nuclear RNA. J. Biol. Chem. 271: 10477–10481, 1996 PubMed: 96209965
 RF42879: Fox JC and Shanley JR. Antisense inhibition of basic fibroblast growth factor induces apoptosis in vascular smooth muscle cells. J. Biol. Chem. 271: 12578–12584, 1996 PubMed: 96218185
 RF42884: Lee MJ et al. The inducible G protein-coupled receptor edg-1 signals via the Gi/mitogen-activated protein kinase pathway. J. Biol. Chem. 271: 11272–11279, 1996 PubMed: 96212194
 RF42945: Marchand P et al. Cysteine mutations in the MAM domain result in monomeric meprin and alter stability and activity of the proteinase. J. Biol. Chem. 271: 24236–24241, 1996 PubMed: 96394562
 RF42958: Arai H and Charo IF. Differential regulation of G-protein-mediated signaling by chemokine receptors. J. Biol. Chem. 271: 21814–21819, 1996 PubMed: 96355570
 RF42959: Huang Q et al. Substrate recognition by tissue factor-factor VIIa. J. Biol. Chem. 271: 21752–21757, 1996 PubMed: 96355561
 RF42976: Montecinos FS and Charo IF. The amino-terminal extracellular domain of the MCP-1 receptor, but not the RANTES/MIP-1alpha receptor, confers chemokine selectivity. J. Biol. Chem. 271: 19084–19092, 1996 PubMed: 96325007
 RF42977: Keith DE et al. Morphine activates opioid receptors without causing their rapid internalization. J. Biol. Chem. 271: 19021–19024, 1996 PubMed: 96324996
 RF50113: Louis N et al. Cloning and sequencing of the cellular-viral junctions from the human adenovirus type 5 transformed 293 cell line. Virology 233: 423–429, 1997 PubMed: 97360037

Propagation:	ATCC medium: Minimum essential medium Eagle with 2 mM L-glutamine and Earle's BSS adjusted to contain 1.5 g/L sodium bicarbonate, 0.1 mM non-essential amino acids, and 1.0 mM sodium pyruvate, 90% heat-inactivated horse serum, 10% Temperature: 37°C
Related Products:	Recommended medium (without the additional supplements or serum described under ATCC Medium) — ATCC 30-2003 purified DNA 45504 purified DNA 45505 derivative CRL-10852
BioSafety:	Handle as potentially biohazardous material under at least Biosafety Level 2 containment
BioSafety Level:	2

Required Forms:	These cells are distributed for research purposes only. The McMaster University releases the line subject to the following 1) 293 cells or their products must not be distributed to third parties. Commercial interests are the exclusive property of the McMaster University. 2) Any proposed commercial use of these cells must first be negotiated with Microbix Biosystems Inc. [contact Kevin Koole], 341 Bering Avenue, Toronto, Ontario, Canada M8Z 3AB Telephone: 416-234-1624, FAX: 416-234-1626, E-mail: customer.service@microbix.com, WWW: Microbix
Shipped:	Frozen
Price:	\$167.00
Revised :	Apr 24, 2001

While ATCC uses reasonable efforts to include accurate and up-to-date information on this site, ATCC makes no warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. ATCC does not warrant that such information has been confirmed to be accurate.

All prices are listed in U.S. dollars and are subject to change without notice. A discount off the current list price will be applied to most cultures for nonprofit institutions in the United States and Canada. Cultures that are ordered as test tubes or flasks will carry an additional laboratory fee. Fees for permits, shipping, and handling may apply.

Customers in Europe, Australia, Japan, Korea, New Zealand and Taiwan must contact a local distributor for pricing information and to place an order for ATCC cultures and products.

Questions or Comments?

(C) 2002 American Type Culture Collection (ATCC)
All rights reserved.

